Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Vomiting 4Nausea 3Gastrointestinal Neoplasms 3Colorectal Neoplasms 2Colonic Neoplasms 2Rectal Neoplasms 1Pancreatic Neoplasms 1Lymphoma 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 685130-nm albumin-bound paclitaxel 199Fluorouracil 190Oxaliplatin 177Albumin-Bound Paclitaxel 154Capecitabine 137Leucovorin 133Irinotecan 114Radiotherapy 96Taxes 85pembrolizumab 81Cisplatin 73Erlotinib Hydrochloride 70Radiosurgery 69Nivolumab 56Drug Therapy 56Bevacizumab 54Magnetic Resonance Spectroscopy 51Cyclophosphamide 50folfirinox 45Specimen Handling 43Docetaxel 42Cetuximab 40Biopsy 39irinotecan sucrosofate 38S 1 (combination) 36Pancreaticoduodenectomy 35Blood Specimen Collection 34Surgical Procedures, Operative 31Paclitaxel 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Aprepitant × Gastrointestinal × Clear all
NCT01534637 2018-08-15

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Wake Forest University Health Sciences

Phase 2 Completed
22 enrolled 9 charts
Gastrointestinal

Bile Duct Neoplasms, Nausea, Pancreatic Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡